Discontinued — last reported Q1 '26
Business Segments · Income Before Taxes
Pharmaceutical — Income Before Taxes
Merck & Co. Pharmaceutical — Income Before Taxes increased by 0.3% to $11.52B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.5%, from $10.71B to $11.52B. Over 4 years (FY 2021 to FY 2025), Pharmaceutical — Income Before Taxes shows an upward trend with a 10.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityStable
First reportedQ1 2016
Last reportedQ1 2026
Rolls up toPre-Tax Income
How to read this metric
An upward trend indicates strong operational execution and effective cost management.
Detailed definition
The total profit generated by the pharmaceutical segment after accounting for all operating and non-operating expenses,...
Peer comparison
The standard measure for comparing the bottom-line performance of operating segments across diversified companies.
Metric ID:
mrk_segment_pharmaceutical_segment_income_before_taxesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.26B | $8.61B | $7.56B | $9.50B | $9.17B | $9.59B | $8.59B | $9.14B | $9.85B | $10.41B | $9.48B | $10.90B | $11.20B | $11.55B | $10.88B | $10.71B | $11.01B | $12.54B | $11.49B | $11.52B |
| QoQ Change | — | +18.6% | -12.2% | +25.7% | -3.5% | +4.5% | -10.4% | +6.4% | +7.8% | +5.6% | -8.9% | +15.0% | +2.7% | +3.1% | -5.8% | -1.6% | +2.8% | +13.8% | -8.4% | +0.3% |
| YoY Change | — | — | — | — | +26.4% | +11.4% | +13.6% | -3.8% | +7.4% | +8.5% | +10.4% | +19.3% | +13.7% | +11.0% | +14.8% | -1.8% | -1.7% | +8.6% | +5.6% | +7.5% |
Range$7.26B – $12.54B
CAGR+10.2%
Avg YoY Growth+9.4%
Median YoY Growth+9.5%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s pharmaceutical — income before taxes?
- Merck & Co. (MRK) reported pharmaceutical — income before taxes of $11.52B in Q1 2026.
- How has Merck & Co.'s pharmaceutical — income before taxes changed year-over-year?
- Merck & Co.'s pharmaceutical — income before taxes increased by 7.5% year-over-year, from $10.71B to $11.52B.
- What is the long-term trend for Merck & Co.'s pharmaceutical — income before taxes?
- Over 4 years (2021 to 2025), Merck & Co.'s pharmaceutical — income before taxes has grown at a 10.2% compound annual growth rate (CAGR), from $30.98B to $45.75B.
- What does pharmaceutical — income before taxes mean?
- The total profit of the pharmaceutical segment before accounting for taxes.